MOUNJARO Eli Lilly Australia Pty Ltd
Product name
MOUNJARO
Sponsor
Accepted date
Feb-2025
Active ingredients
tirzepatide
Proposed indication
For the treatment of symptomatic chronic heart failure.
Application type
C (new indication)
Publication date
Feb-2025